Polarean Imaging PLC (LON:POLX) announced that Dr Jonathan Allis has assumed the role of non-executive chairman of the clinical stage medical imaging technology company with immediate effect.
In a statement, the AIM-listed firm – which is developing a proprietary magnetic resonance imaging (MRI) drug-device combination – noted that Dr Allis has a wealth of direct knowledge in healthcare and the medical imaging contrast agent industry and is currently the founder and chief executive officer of Blue Earth Diagnostics, which was recently acquired by Bracco Imaging for US$450mln.
READ: Polarean Imaging scores phase III success
Richard Hullihen, Polarean’s chief executive officer commented: "The Company welcomes Jonathan Allis stepping up to Chairman ahead of the next phase of Polarean's lifecycle as we move toward regulatory submission and proposed commercial launch.
“Prior to founding Blue Earth, Jonathan was the General Manager for PET at GE Healthcare Life Sciences and in previous roles with GE, was responsible for their hyperpolarised Xenon business, which is now owned by Polarean."
The group said Dr Allis’s appointment follows the resignations of both Richard Morgan the company's previous non-executive chairman and Robert Bertoldi, another non-executive director, from the company's board with immediate effect.
Hullihen said: "The Board would like to sincerely thank Richard and Bob for their guidance and service during the intense process of the Company's formation, launch and early stage development. Their leadership was invaluable in listing, the fundraising process and the successful completion of the Company's Phase III clinical trials. We wish them well in their future endeavours.”
Polarean pointed out that it has commenced the search for a new non-executive director and will make a further announcement in due course.